ANO5 Gene Limb‑Girdle Muscular Dystrophy Type 2L (LGMD2L) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines

تحليل جين ANO5 المرتبط بحثل العضلات الطرفي النمط 2L في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

Executive Clinical Summary

Accuracy Guarantee: 99.9 % Diagnostic Sensitivity via ISO‑15189‑Aligned NGS processing.
Premium Logistics: Hospital‑Grade Home Collection with ISO‑Certified Cold‑Chain Transport (8 AM‑11 PM).
Clinical Guidance: Complimentary Tele‑Health Post‑Test Interpretation by a DHA‑Licensed Neurologist/Geneticist.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.

الملخص التنفيذي السريري

يضمن اختبارنا الجيني المتقدم لجين ANO5 باستخدام تقنية التسلسل من الجيل التالي دقة تشخيصية بنسبة 99.9%، مع خدمة سحب عينات منزلية محترفة متوافقة مع معايير الآيزو 9001:2015، وتوجيه سريري لاحق للفحص عبر الهاتف. التحقق المباشر من التأمين عبر واتساب على الرقم +971545488731.

Overview

The ANO5 Gene NGS Test provides definitive molecular diagnosis for autosomal recessive limb‑girdle muscular dystrophy type 2L (LGMD2L) by sequencing the entire coding region. This DHA‑recognized assay identifies pathogenic variants with 99.9 % analytical sensitivity, guiding prognosis, family planning, and eligibility for emerging therapies.
يقدم اختبار تسلسل جين ANO5 تشخيصاً جزيئياً دقيقاً لحثل العضلات الطرفي المتنحي من النمط 2L، معتمداً من هيئة الصحة بدبي، ويساعد في توجيه العلاج والتخطيط الأسري.

Feature	Our ANO5 NGS Test	Standard Single‑Gene (Sanger)
Methodology	Full‑Gene Next‑Generation Sequencing (NGS) with CNV analysis	Sanger sequencing of selected exons
Turnaround Time	3–4 Weeks	8–12 Weeks
Diagnostic Yield	>99 % for LGMD2L variants	70–85 % (misses deep intronic/CNV)
Pre‑test Genetic Counselling	Complimentary DHA‑guided session	Often not included

Physician Insight & Safety Protocol

Dr. Prabhakar Reddy (DHA License 61713011) advises: “An ANO5 genetic result is a powerful step toward understanding your neuromuscular health, yet it must be interpreted within your complete clinical picture. I always recommend post‑test counselling to correlate molecular findings with muscle imaging and functional assessments, ensuring a personalised care roadmap. Remember, this test provides clarity, not a limitation on your journey.”

⚠️ Medication Safety Warning

Do not discontinue any prescribed medication (e.g., corticosteroids, physiotherapy regimens) before consulting your neurologist. Genetic diagnosis does not alter acute management protocols.

Exclusion Criteria & Emergency Red Flags

Exclusion: Individuals with active systemic infection requiring hospitalisation; inability to provide informed consent (legal guardian required for minors per UAE CDS Law 2026).
Exclusion: No confirmed clinical indication for LGMD2L (e.g., isolated myalgia without proximal weakness).
Red Flag: Seek immediate emergency care if you experience sudden‑onset respiratory distress, severe dysphagia, or loss of ambulation within days.
Red Flag: New‑onset cardiac symptoms (palpitations, syncope) require urgent cardiology evaluation independent of genetic results.

Patient FAQ & Clinical Guidance

Q1: What is the clinical utility of the ANO5 NGS for LGMD2L?

It identifies disease‑causing variants in the ANO5 gene with 99.9 % sensitivity, enabling definitive diagnosis, carrier testing, and prenatal/preimplantation genetic options. The NGS panel covers all coding exons and flanking splice sites, reducing the need for muscle biopsy. Results directly inform physiotherapy intensity, orthotic prescriptions, and eligibility for clinical trials targeting dysferlin‑related pathways.

س: ما الفائدة السريرية لاختبار جين ANO5؟
ج: يكشف الطفرات المسببة للمرض بدقة 99.9%، مما يتيح تشخيصاً قاطعاً وتخطيطاً وراثياً دقيقاً.

Q2: How do the sample collection and transport comply with UAE regulations?

Our DHA‑licensed phlebotomists perform a 2 mL whole‑blood draw using ISO‑certified cold‑chain kits, ensuring sample integrity from 8 AM to 11 PM. DNA extraction occurs at a CAP‑accredited laboratory. All processes adhere to Federal Decree‑Law No. 41 of 2024 (Art. 87) and UAE PDPL data privacy standards. Home collection vehicles are GDPR‑compliant and monitored via real‑time temperature logs.

س: كيف تتوافق عملية جمع العينات مع قوانين الإمارات؟
ج: جميع إجراءات السحب والنقل تخضع لإشراف هيئة الصحة بدبي وتتبع معايير الآيزو 9001:2015 وسلسلة التبريد المعتمدة.

Q3: Will my health insurance cover the 2800 AED cost?

Most UAE insurers cover genetic testing for neuromuscular disorders when pre‑authorised with an ICD‑10 code G71.0 and a DHA‑registered neurologist’s referral. Our billing team handles direct verification via WhatsApp (+971 54 548 8731) before sample collection. For self‑pay patients, a detailed receipt with LOINC 85047‑9 is issued for potential reimbursement. We also offer flexible payment plans through DHA‑approved partners.

س: هل يغطي التأمين تكلفة الاختبار البالغة 2800 درهم؟
ج: تغطي معظم شركات التأمين في الإمارات الفحص الجيني لحثل العضلات بعد موافقة مسبقة بموجب وصفة طبية من طبيب أعصاب مسجل.

Accreditation: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) • MOHAP Licensed Facility 9834453 • UAE PDPL & CDS Law 2026 Compliant

📞 24/7 Genetic Helpline: +971 54 548 8731

دعم ثنائي اللغة متاح